Xu Zhenyu sold $32K of SOPH
Xu Zhenyu (Chief Scientific Officer) sold 4,000 shares of SOPHiA GENETICS SA (SOPH) at $7.96 on 2026-11-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is pre-arranged, it typically has lower informational content than discretionary selling. Traders may still monitor for patterns, but this single transaction alone is unlikely to change SOPH’s fundamental outlook.
Market read
A disclosed insider sale provides a small sentiment datapoint, but no new business, financial, or regulatory information is presented.
What to watch
The article does not disclose whether other insiders sold/bought around the same time, nor does it provide context on total insider holdings beyond the post-transaction figure.
Background
The filing is an SEC Form 4 insider transaction by SOPHiA Genetics CSO Xu Zhenyu, executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Insider Form 4 shows CSO Xu Zhenyu sold 4,000 shares of SOPHiA Genetics at $7.9553 on 2026-11-13 under a 10b5-1 plan.
Likely limited near-term impact, with any effect driven by trader interpretation of insider selling rather than new company fundamentals.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and the disclosed size is modest relative to typical large-cap price-setting flows.
Market effects
Minimal, as this is company-specific insider trading with no disclosed operational or regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still coincide with management’s view of near-term valuation risk, so some traders may treat it as a mild bearish signal.
Key entities
- issuerSOPHiA GENETICS SA
Company whose shares were sold by an insider under a Rule 10b5-1 plan.
- insiderXu Zhenyu
Chief Scientific Officer who executed the open-market sale.



